anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants in this condition will be told that the device they will be testing is merely a prototype that they are testing for design purposes. However, these participants will also be told that their input while wearing the device will help the team in developing the final device and allow the team to focus on how to best improve hearing. All participants will be instructed to put on the hearing device and listen to an audio twice per day for 6 days. After listening to the 2nd audio of the day, they will be asked 1) to note any changes in what they heard in the audio focusing on the story in the ballad and 2) whether their hearing might possibly be impacted by activities and behavior. They will also be asked 3) about their general health and wellness, as compared to the last time they were contacted by email. This condition will enable researchers to test the main effect of attention to variability, without an explicit placebo effect.
This is a prospective, randomized, unblinded, controlled study of early, high-dose iron for neuroprotection in extremely preterm infants born between 24 0/7 weeks and 30 6/7 weeks gestation. This study has chosen to study newborns between 24-0/7 and 30-6/7 weeks of gestation because of (1) high likelihood of poor outcome, (2) highest risk of iron deficiency and potentially most likely to benefit from intervention based on their stage of brain development, (3) previously studied to assess safety of this iron regimen in Preterm Erythropoietin Neuroprotection Trial (PENUT) protocol, and (4) absence of therapeutic interventions to improve neurodevelopmental outcome. Study sample size is 90 patients; to be enrolled at Ann \& Robert H Lurie Children's Hospital-Prentice Women's Hospital. We expect to evaluate 82 infants at 10-14 months and 22-26 months corrected age, our primary endpoints. There is no enrollment restriction based on race, ethnicity or gender. Enrollment is expected to take 18-24 months, with each subject with each subject participating through 24-26 months corrected age when final neurodevelopmental outcomes are assessed. Subjects will be randomized locally to regular-dose iron as recommended by AAP or early, high-dose iron. High-dose iron will continue until 36 weeks corrected age. Serial measurements of hemoglobin, reticulocyte count, reticulocyte hemoglobin equivalent and ferritin levels will be obtained, starting 2 weeks after starting iron supplementation, with final measurement obtained at 40 weeks corrected age or prior to discharge, whichever is first. Data will be abstracted regarding interval medical history from the electronic medical record. After discharge, Neonatal Intensive Care Unit (NICU) developmental follow-up will occur at 12 months and 24 months corrected age, at which time standardized neurodevelopmental assessments will be performed. The outcome measure is neurodevelopmental outcome at 10-14 months and 22-26 months of age. Our estimated sample size is based on the assumption that early high dose iron supplementation will reduce abnormal neurological outcome by 16%-29%, and taken together with an estimated 10% anticipated loss due to unrelated deaths, the total sample size was calculated at 90 infants (45 in each arm of the study).
Asthma, the most prevalent chronic disease in pediatric age, continues to pose challenges in its management and treatment. National and international guidelines emphasize the importance of therapeutic education (TE) to achieve disease control. TE involves imparting knowledge and skills to the patient and their family, enhancing medication adherence, rectifying errors in inhalation technique, and tailoring treatment based on individual patient characteristics. It is essential for TE to be progressive, gradual, and personalized, spanning all levels of care. Training healthcare professionals in TE is crucial, particularly for pediatricians, who must also be aware of the extensive variability of available meds and inhalers and their respective age-specific indications. Addressing this need, the REGAP Group extensively reviewed inhalers currently available in Spain for pediatric asthma treatment. The review encompassed different inhalation systems and inhaled drugs used for pediatric asthma treatment. This review will be updated annually, providing information on medications, devices, inhalation chambers, indications, and financiation. The REGAP Group hopes that these tables will be a valuable help for pediatricians in their daily clinical practice and serve as an effective TE tool.
The study group will consist of two cohorts, those presenting with tooth wear and a control group. Participants will be recruited from the care planning clinic of the Dental Institute King's College London. Suitable participants meeting the inclusion criteria will be approached on the clinic, given the patient information sheet and asked to consider participating. Written consent will be obtained from those accepting the request. An interviewer-led, previously validated questionnaire will question their frequency and timing of dietary acid intake, tooth brushing and any habits associated with dietary acid intake. This will be followed by a Basic Erosive Wear Examination.

The process will take 7-8 minutes and the participant is free to withdraw at any time
This clinical trial is testing a drug called Tocilizumab (a monoclonal antibody) as a first line therapy for subjects with steroid-refractory acute graft versus host disease (acute GVHD) after undergoing a bone marrow transplant. The purpose of the study is to test the safety and efficacy of Tocilizumab at differing dose schedules. There are 2 phases to this study. Both phases include subjects with acute GVHD have not responded to steroid treatment. Subjects enrolled in Phase IIp will receive Tocilizumab 8 mg/kg every week or every 2 weeks. Subjects enrolled in Phase II will receive one of two dose schedules determined by the results of Phase IIp. Depending on the dose they are assigned to, subjects will receive Tocilizumab every week or every 2 weeks for a total of 8 doses. The study medication may be interrupted, withheld or stopped for different reasons. However, subjects will be asked to follow up periodically for one year after starting Tocilizumab treatment.
In a 2-year rat carcinogenicity study, ritlecitinib increased the incidence of combined benign and malignant thymomas in female rats, and thyroid follicular adenomas and combined follicular adenomas and carcinomas in male rats at 100 mg/kg/day (29 times the MRHD based on AUC comparison). No ritlecitinib-related tumors were noted at doses up to 30 mg/kg/day (6.3 times the MRHD based on AUC comparison). No ritlecitinib-related tumors were noted in a 6-month Tg.rasH2 mouse carcinogenicity study at doses up to 300 mg/kg/day.

Ritlecitinib was not mutagenic in the in vitro bacterial reverse mutation assay (Ames assay). Ritlecitinib was positive in an in vitro micronucleus assay in TK6 cells. However, mechanistic studies determined that ritlecitinib is aneugenic and does not present a clinically relevant genotoxic concern. Additionally, in an in vivo rat bone marrow micronucleus assay, ritlecitinib was not aneugenic or clastogenic at doses up to 400 mg/kg/day.

Ritlecitinib had no effects on female rat fertility at doses up to 200 mg/kg/day (55 times the MRHD based on AUC comparison). Effects on male rat fertility were noted (higher preimplantation loss resulting in lower number of implantation sites and corresponding lower litter size in naïve females mated with ritlecitinib-dosed males) at 200 mg/kg/day (55 times the MRHD based on AUC comparison). No effects on male fertility were noted at doses up to 60 mg/kg/day (14 times the MRHD based on AUC comparison). No effects on spermatogenesis (sperm counts, production rate, motility, or morphology) were noted at any dose.
In acupressure, "cun" is used as the unit of measurement to determine the points to be applied. In order to find the acupressure points correctly, measurements should be made using the individual's own fingers. The thumb widths of the individuals participating in the study will be measured and converted as centimeter 1 cun unit. The points to be used in acupressure will be Shen Men (HT7) located in the transverse wrist crease, in the small depression between the pisiform and ulna bones, (LI11) located at the end of the crease when the elbow is bent, and Hegu (LI4) located in the space between the thumb and index finger will be marked by the certified researcher (GB) with an acetate pen in the patients in the study group. And the application will be performed by the certified researcher (GB).
The invention discloses an external contraceptive for preventing and treating lower genital tract infection and a preparation method thereof. The medicament is prepared from the following raw material medicaments in part by weight: 10-40 parts of phellodendron, 10-40 parts of ginkgo, 30-120 parts of black nightshade, 20-60 parts of dandelion, 30-120 parts of herba patriniae, 10-40 parts of dittany bark, 30-120 parts of glabrous greenbrier rhizome, 10-25 parts of mint, 1.0-2.5 parts of borneol and 10-40 parts of tree peony bark. The invention not only can effectively prevent and treat lower genital tract infection, but also has the effect of killing sperm externally. The invention has the function of protecting vagina and the functions of preventing and treating genital tract inflammation and lubricating. The invention has the function of killing or inhibiting common pathogenic bacteria and partial sexually transmitted infectious disease sources in the vagina and has little influence on lactic acid bacteria. Compared with the existing spermicidal product for the simple vagina, the spermicidal composition has less discomfort reaction such as local stimulation.
Disclosed herein are system, method, and computer program product embodiments for adaptive specimen collection order processing. An embodiment operates by retrieving a specimen order for processing a specimen collection. The specimen order comprises a test code. The embodiment determines that the specimen order is an eligible specimen order by determining that the test code matches at least one of a plurality of qualifying test codes. The embodiment transmits, to an electronic patient system, a request to provide resource allocation information for processing the specimen collection associated with the eligible specimen order. The embodiment generates an event for performing the specimen collection that satisfies the resource allocation information. The embodiment retrieves digital evidence that the event was completed. The embodiment validates that the event was completed based on the retrieved digital evidence. The embodiment then updates the eligible specimen order with a completion test code indicating the specimen collection was completed.
Dosage may be initiated at 50 mcg three times a day. Beginning with this low dose may permit adaptation to adverse gastrointestinal effects for patients who will require higher doses. IGF-I (somatomedin C) levels every 2 weeks can be used to guide titration. Alternatively, multiple growth hormone levels at 0 to 8 hours after octreotide acetate injection administration permit more rapid titration of dose. The goal is to achieve growth hormone levels less than 5 ng/mL or IGF-I (somatomedin C) levels less than 1.9 unit/mL in males and less than 2.2 unit/mL in females. The dose most commonly found to be effective is 100 mcg three times a day, but some patients require up to 500 mcg three times a day for maximum effectiveness. Doses greater than 300 mcg/day seldom result in additional biochemical benefit, and if an increase in dose fails to provide additional benefit, the dose should be reduced. IGF-I (somatomedin C) or growth hormone levels should be reevaluated at 6 month intervals. 

Octreotide acetate injection should be withdrawn yearly for approximately 4 weeks from patients who have received irradiation to assess disease activity. If growth hormone or IGF-I (somatomedin C) levels increase and signs and symptoms recur, octreotide acetate injection therapy may be resumed.
FIELD: medicine, ophthalmology, homeopathy. SUBSTANCE: agent has medicinal substances prepared by homeopathy procedure and taken in potentiated doses and neutral carrier. Agent has Secale cornutum, Agaricus, Silicea as drugs and additionally it has Magnesia phosphorica and Arnica depending on patient age, visual loading and type of vegetovascular dystonia course. All medicinal components are taken in dilution C6. Agent ensures to eliminate ciliary muscle spasm, enhance effectiveness of spasm of accommodation treatment, prolong remission periods, prevent relapses of accommodative pseudo-myopia. Agent shows the purposeful effect on ciliary muscle, normalizing its tonus and increasing its working ability, and on vegetative nervous system eliminating its disbalance. EFFECT: development of homeopathic agent used for treatment of disorders indicated above. 4 cl, 1 tbl, 2 ex
Increased levels of bad cholesterol in the body result in increasing blood pressure and weight gain. The rate of mortality in people, especially who are obese, is increasing due to absence of organic sources of fiber in their diets. Chia and fennel seeds are rich sources of fiber. The objective of this study was to evaluate the combined effect of Salvia hispanica (Chia seeds) and Foeniculum vulgare (Fennel seeds) against weight-loss and lipid profile in obese human subjects. The research was conducted on obese people aged 25 to 40 years at the Jinnah Hospital Lahore. The study design was randomized control trial (RCT). The sample size was calculated and was divided in-to two groups. With the duration of study being 3 months, pre-testing of all the participants was done. Group 1 was control group, given placebo treatment and Group 2 was an intervention group and given chia and fennel seeds. Post-testing was done and data were analyzed. Results showed that chia and fennel seeds have significant effect (p <0.05) on BMI and lipid profile hence, both are beneficial for lowering body weight and improving LDL, HDL, serum triglycerides and total cholesterol levels.
Sarcopenia is prevalent among 11-25% of adult cancer survivors, depending on the cancer type, although the available data on post-treatment survivors in Japan are limited. If cancer patients develop cachexia, they may experience sustained weight loss as a result, ultimately leading to sarcopenia. Conversely, some patients experience post-treatment weight gain, resulting in sarcopenic obesity. Both sarcopenia and obesity elevate the risk of cardiovascular diseases and mortality; therefore, the importance of sarcopenia prevention and management is undeniable. The Guidelines for Exercise for Cancer Survivors recommend continued physical activity. Recent studies have reported the effectiveness of multimodal interventions, combining pharmacological, nutritional, and exercise approaches, necessitating multidisciplinary care for post-treatment sarcopenia. Innovative health interventions using mobile devices have also gained attention. However, studies on sarcopenia in post-treatment cancer survivors, especially those regarding exercise interventions, remain scarce in Japan, primarily due to limited insurance coverage for such post-treatment interventions and workforce challenges. It is clear that some cancer survivors have sarcopenia, which can lead to worse survival and secondary illness. While the benefits of exercise are clear, a comprehensive approach to sarcopenia is a further challenge for the future.
The invention provides a medicine for treating or preventing Acute Lymphoblastic Leukemia (ALL) drug-resistant relapse and application thereof. The drug acts on enzymes in the purine synthesis pathway, and reduces the drug-resistant relapse of ALL by reducing the concentration of hypoxanthine. The invention also provides application of the compound Lometrexol (Lometrexol) and related targeted GART and ATIC preparations in preparation of medicines for preventing or treating ALL drug-resistant relapse. The invention also provides a kit for evaluating the risk of ALL drug-resistant relapse and a using method thereof, wherein the kit comprises a reagent for cracking sample cells and an instruction for using. The using method comprises the following steps: (1) collecting and cracking sample cells; (2) detecting the content of hypoxanthine, IMP, AICAR and inosine; (3) and judging the risk of drug resistance relapse of the sample acute lymphocytic leukemia. The invention provides powerful technical means and support for preventing and treating ALL drug-resistant relapse.
The study was planned as a block randomized controlled experimental study. In order to calculate the sample size needed in our study, a pilot study will be conducted and a priori power analysis will be made based on the results of this study.

E-mobile application will be used as data collection tool. The "E-Mobile Application Training Content Guide" to be integrated into the mobile application will be evaluated by the experts with the "Conformity Evaluation Form of Written Training Materials" and the "DISCERN Scale". After the training content is completed, "Personal Information Form", "STAI State and Trait Anxiety Scale", "Assessment and Monitoring Form for Daily Living Activities" will be used. In the preliminary application, the "System Usability Scale" and the e-mobile application will be evaluated by the patients. The "E-Mobile Application Training Content Guide" created by the researchers in line with the literature will be transferred to the mobile application with the help of computer engineers and graphic designers. Sequence and visuality of education Roper et al. It was designed according to the Life Activities Based Nursing Model developed by The e-mobile application is designed in accordance with the Android operating system and its language is Turkish. Patients who download the application from the virtual market (Google Play) can log in with the user name and password created by the researcher. The user name and password were created by the researcher specifically for each patient during the research process. The number of clicks and the reading time of the topics read by the patients entering the application can be tracked with the help of the created web page. The research will be carried out with 2 groups as application (mobile application) and control (standard care).
The investigators will recruit survivors of childhood leukemia with DS to participate in a one-time assessment of neurocognitive and psychosocial functioning. Potentially eligible families will be identified via medical record review at St. Jude Children's Research Hospital (SJCRH) and contacted to discuss study objectives, assess interest, and confirm eligibility. Eligible families will be scheduled for one study visit, estimated to last about 2.5 hours. Participants will provide informed consent prior to the start of any study procedures. Survivors who are ≥ 5 years old will complete performance-based neurocognitive measures. Caregivers (i.e., parents or legal guardians) of all participants, regardless of age, will complete ratings of executive function, behavior, and adaptive skills. Participants will be asked to identify and provide written permission to contact a secondary informant (e.g., teacher or work supervisor). Identified informants will be contacted by study team members and asked to complete behavior rating scales.
The ACT intervention will include: 1) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts such as "I can't take this pain anymore" or "This is unfair") and learning how to willingly face experiences that cannot be changed; and 2) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise. The workshop will also include information on pain and pain control post-TKA.
When radiculopathy occurs due to compression of the neck nerve roots due to pathologies in the neck, it is called cervical radiculopathy. It is thought that high and low BMI values have an impact on radiculopathy. The pressure exerted by fatty tissue on muscle tissue can significantly affect the nerves. This causes an increase in radiculopathy symptoms. Therefore, high BMI causes an increase in the incidence of radiculopathy. The relationship between the degree of obesity, visceral fat area, body mass index, abdominal circumference, and lumbar disc herniation and pain is shown. It has been stated in the literature that BMI is related to lumbar radiculopathy and pain level. Still, there appear to be inadequacies in examining its relationship with radiculopathy, which is related to upper extremity functionality. Therefore, it is thought that pain caused by cervical radiculopathy may be associated with BMI and affect functionality more. At the same time, as BMI increases, lumbar lordosis may affect spine biomechanics, leading to deterioration in sagittal balance and an increase in cervical problems. According to an international study It is stated that in obese individuals with high BMI values, vertebral discs undergo degeneration due to the load on the spine.

For this reason, researchers have suggested that pain level increases linearly with BMI value. It is stated that degenerating lumbar vertebrae progress to narrowing over time and that the risk of lumbar spinal stenosis may increase in individuals with high-fat content. Therefore, radiculopathy is thought to be a significant factor when looking at the relationship between pain in the musculoskeletal system and BMI.
PURPOSE: A stable and taste masked pharmaceutical dosage form including porous apatite grains and a drug entrapped in pores of the grains is provided. It exhibits its stable medicinal efficacy even when stored for a long period of time and permits encapsulation of drugs with an unpleasant taste, thereby permitting easier swallowing of drugs. CONSTITUTION: The stable and taste masked pharmaceutical dosage form contains porous apatite grains, 0.1 to 45% by weight of a drug entrapped in pores of the grains and additionally 0.1 to 10% by weight of water-soluble polymers, based on the weight of the grains, wherein the grains have a size of 0.1 to 1,000μm and the pores of the grains have an opening of 0.5 to 300μm. The grains have a specific surface area of 32 to 58m¬2 per unit gram. The drug is zinc gluconate, copper gluconate, aspirin, ibuprofen or ascorbic acid. The water-soluble polymer is selected from the group consisting of chitosan, gelatin, agar, cellulose, chitin, starch, dextrin, cyclodextrin, polylactic acid, poly(amino) acid, polyethylene glycol, polyacrylate, hyaluronic acid, polyvinyl alcohol, povidone.